

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

c-Myc (N-262)

RRID:AB_631276

Type: Antibody

Proper Citation

Santa Cruz Biotechnology Cat# sc-764, RRID:AB_631276

Antibody Information

URL: http://antibodyregistry.org/AB_631276

Proper Citation: Santa Cruz Biotechnology Cat# sc-764, RRID:AB_631276

Target Antigen: c-Myc (N-262)

Host Organism: rabbit

Clonality: polyclonal

Comments: Discontinued: 2016; validation status unknown check with seller; recommendations: IgY Immunoprecipitation; Immunofluorescence; Western Blot; ELISA; WB, IP, IF, ELISA

Antibody Name: c-Myc (N-262)

Description: This polyclonal targets c-Myc (N-262)

Target Organism: monkey, rat, mouse, human

Antibody ID: AB_631276

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-764

Record Creation Time: 20231110T080345+0000

Record Last Update: 20260830T015922+0000

Ratings and Alerts

- ENCODE PROJECT External validation for lot: H0107 is available under ENCODE ID: ENCAB000AET - ENCODE

<https://www.encodeproject.org/antibodies/ENCAB000AET>

Warning: Discontinued: 2016

Discontinued: 2016; validation status unknown check with seller; recommendations: IgY Immunoprecipitation; Immunofluorescence; Western Blot; ELISA; WB, IP, IF, ELISA

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 41 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Tiwari PK, et al. (2026) An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. Cell reports, 45(6), 117464.

Cigrang M, et al. (2025) Pan-inhibition of super-enhancer-driven oncogenic transcription by next-generation synthetic ecteinascidins yields potent anti-cancer activity. Nature communications, 16(1), 512.

Li Q, et al. (2024) A helicase-independent role of DHX15 promotes MYC stability and acute leukemia cell survival. iScience, 27(1), 108571.

Ding J, et al. (2024) MYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress during Cancer Development. Cancer research, 84(23), 4031.

Yoshida Y, et al. (2024) Sugar-mediated non-canonical ubiquitination impairs Nrf1/NFE2L1 activation. Molecular cell, 84(16), 3115.

Wang H, et al. (2023) Premature aging and reduced cancer incidence associated with near-complete body-wide Myc inactivation. Cell reports, 42(8), 112830.

Martin BJE, et al. (2023) Global identification of SWI/SNF targets reveals compensation by EP400. Cell, 186(24), 5290.

Tao L, et al. (2022) MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma. Nature communications, 13(1), 3728.

Daniel CJ, et al. (2022) T-cell Dysfunction upon Expression of MYC with Altered Phosphorylation at Threonine 58 and Serine 62. Molecular cancer research : MCR, 20(7), 1151.

Guo R, et al. (2022) Methionine metabolism controls the B cell EBV epigenome and viral latency. Cell metabolism, 34(9), 1280.

Poeta E, et al. (2021) Histone Acetylation Defects in Brain Precursor Cells: A Potential Pathogenic Mechanism Causing Proliferation and Differentiation Dysfunctions in Mitochondrial Aspartate-Glutamate Carrier Isoform 1 Deficiency. *Frontiers in cellular neuroscience*, 15, 773709.

Gong C, et al. (2021) Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. *Molecular cell*, 81(19), 4059.

Sharpley MS, et al. (2021) Metabolic plasticity drives development during mammalian embryogenesis. *Developmental cell*, 56(16), 2329.

Latif AL, et al. (2021) BRD4-mediated repression of p53 is a target for combination therapy in AML. *Nature communications*, 12(1), 241.

Vannam R, et al. (2021) Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. *Cell chemical biology*, 28(4), 503.

Papathanasiou M, et al. (2021) Identification of a dynamic gene regulatory network required for pluripotency factor-induced reprogramming of mouse fibroblasts and hepatocytes. *The EMBO journal*, 40(1), e102236.

Ireland AS, et al. (2020) MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. *Cancer cell*, 38(1), 60.

Guo R, et al. (2020) MYC Controls the Epstein-Barr Virus Lytic Switch. *Molecular cell*, 78(4), 653.

Msaouel P, et al. (2020) Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. *Cancer cell*, 37(5), 720.

Wang LW, et al. (2019) Epstein-Barr-Virus-Induced One-Carbon Metabolism Drives B Cell Transformation. *Cell metabolism*, 30(3), 539.